Signal transduction pathways provide post-receptor mechanisms that allow multiple responses to a hormone such as parathyroid hormone (PTH), for which there is a single receptor. Knowledge of which actions of the hormone are mediated by which pathways can lead to the design of selective therapies to enhance or decrease specific responses. The focus of the current proposal is the role of the phospholipid/diacylglycerol/protein kinase C pathway in parathyroid hormone actions on bone. Evidence suggests that several important actions of parathyroid hormone are likely to be mediated, completely or in part, through this pathway. These actions include the stimulation of IL-6 production, the down-regulation of cAMP production, and the inhibition of collagen synthesis. Thus, activation of this pathway by parathyroid hormone in bone would result in less anabolic action and more resorptive activity. Recent studies in other tissues reveal that the phospholipid/diacylglycerol/PKC pathway is highly diverse. There are several potential phospholipid sources for the diacylglycerol, and 12 recognized PKC isozymes. Methodologies are now available to define the PKC pathway in bone much more precisely than in the past. The hypotheses to be tested are that a) PTH actions to increase IL-6, down-regulate cAMP production, and decrease collagen synthesis are mediated through the PKC pathway and involve activation of specific PKCs, b) that the specificity in PKC activation arises through the specific diacylglycerols being produced, and c) that these specific diacylglycerols are generated through the hydrolysis of different phospholipids, with the sustained effects of PTH being due to hydrolysis of phosphatidylcholine.
The specific aims are thus 1) to characterize phosphatidylcholine hydrolysis in osteoblastic cells in response to PTH, 2) to characterize the changes in PKC isozymes in osteoblastic cells in response to PTH, and 3) to demonstrate the role of specific PKC pathways in actions of PTH on osteoblastic cells. Selective amplification or depression of the proposed pathways and isozymes would be used to test the hypothesis that they are the pathways for the end responses under consideration. The studies would be carried out in UMR-106 osteoblastic osteosarcoma cells and osteoblastic cells obtained from neonatal mouse calvaria. Effects of bPTH(1-34) will be compared to those of bPTH(3-34) and bPTH(7-34)NH/2, which are also agonists on PKC production but have little or no agonist effects on cAMP.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
General Medicine B Study Section (GMB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
Schools of Dentistry
United States
Zip Code
Wang, J; Stern, P H (2011) Dose-dependent differential effects of risedronate on gene expression in osteoblasts. Biochem Pharmacol 81:1036-42
Wang, J; Gilchrist, A; Stern, P H (2011) Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells. Cell Signal 23:380-8
Wang, Jun; Stern, Paula H (2010) Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active G?(12) or constitutively active RhoA. J Cell Biochem 111:1531-6
Yoshida, Tomohiko; Clark, Mary F; Stern, Paula H (2009) The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival. J Cell Biochem 106:896-902
Kazmers, Nikolas H; Ma, Sophia A; Yoshida, Tomohiko et al. (2009) Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells. Bone 45:52-60
Singh, A T K; Gilchrist, A; Voyno-Yasenetskaya, T et al. (2005) G alpha12/G alpha13 subunits of heterotrimeric G proteins mediate parathyroid hormone activation of phospholipase D in UMR-106 osteoblastic cells. Endocrinology 146:2171-5
Dossing, Debra A; Stern, Paula H (2005) Receptor activator of NF-kappaB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol. J Cell Biochem 95:1029-41
Singh, Amareshwar T K; Frohman, Michael A; Stern, Paula H (2005) Parathyroid hormone stimulates phosphatidylethanolamine hydrolysis by phospholipase D in osteoblastic cells. Lipids 40:1135-40
Radeff, Julie M; Nagy, Zsolt; Stern, Paula H (2004) Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. J Bone Miner Res 19:1882-91
Radeff, Julie M; Singh, Amareshwar T K; Stern, Paula H (2004) Role of protein kinase A, phospholipase C and phospholipase D in parathyroid hormone receptor regulation of protein kinase Calpha and interleukin-6 in UMR-106 osteoblastic cells. Cell Signal 16:105-14

Showing the most recent 10 out of 44 publications